People: Kazia Therapeutics Ltd (KZIA.OQ)

KZIA.OQ on NASDAQ Stock Exchange Capital Market

18 Apr 2019
Change (% chg)

$-0.24 (-6.96%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Palmer, Stephen 

Mr. Stephen Palmer is a Program Director - Degenerative Diseases of the company., Since 2014 and is responsible for running the drug discovery programme centred around stimulating regenerative processes in stem cells and developing novel therapies for degenerative diseases including dementia, muscular dystrophy, lysosomal storage disorders and autoimmune disease. Dr Palmer completed his PhD in 1992 at University College London and established a career studying the genetic regulation of embryonic development and inherited disorders. Using genetically modified mice as models of human disease, he has studied normal and abnormal cellular function in several different organ systems. Dr Palmer migrated to Australia on a Wellcome Trust International Travelling Fellowship and worked at the Victor Chang Cardiac Research Institute and the Children’s Medical Research Institute in Sydney. He established a research program on the neurodevelopmental disorder Williams-Beuren syndrome, demonstrating the key role of the GTF2IRD1 protein. He currently holds a conjoint Senior Lectureship at UNSW Australia.

Basic Compensation

Total Annual Compensation, AUD 32,846
Restricted Stock Award, AUD --
Long-Term Incentive Plans, AUD --
All Other, AUD 3,038
Fiscal Year Total, AUD 35,884

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --